# One.Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/one-bio

- Industry: Biotechnology
- Headquarters: Sacramento, US
- Website: www.one.bio
- Total disclosed funding: $43M
- Latest round: Series A (Dec 16, 2024)
- Investors on record: 11

## About

Founded in 2019 and based in California, US, One.Bio formerly known as BCD Bioscience, Inc.,and Calyxo Biosystems offers a range of oligosaccharides with a variety of natural structures, as well as linkages between these structures and their roles as prebiotics and immunomodulatory. BCD Bioscience was formed as a spin-out from UC Davis. In April 2022, BCD Bioscience, Inc. raised USD 11.59 million in Series A funding from Acre Venture Partners including Skyviews Life Science, Collaborative Fund, iSelect Fund Management, and Seventure. As of 2022, Steve Watkins is the CEO of the company. In December 2024, One Bio raised USD 27 million in series A funding led by new investor Alpha Edison, with participation from returning investors Acre Venture Partners, Collaborative Fund, iSelect Fund Management, and Skyviews Life Science. Other new investors DSM-firmenich, E12 Ventures, Leaps by Bayer, Morado Ventures, and ReMy Ventures also participated in the round.
 

The company provides a technology that produces prebiotics from a variety of natural fiber sources, as well as validated its science platform for prebiotic screening for functional properties such as the impact on live biotherapeutics, microbial composition and function, and active metabolites (postbiotics). The firm's platform provides information about carbohydrate structure and bacteria's use of prebiotics and also facilitates partnership and commercialization opportunities in both R&D and late-stage development.

The organization plans to use the April 2022 funding to obtain regulatory approvals for lead products, upscale production capabilities, expand the product pipeline and build a prediction and screening platform.

## Funding rounds

- Series A, Dec 16, 2024, $27M — Morado Ventures, Collaborative Fund, iSelect Fund Management, Acre Venture Partners, Alpha Edison, Leaps by Bayer, Skyviews Life Science, ReMy Ventures, E12 Ventures, DSM-firmenich
- Series A, Feb 24, 2022, $12M — Seventure Partners, Collaborative Fund, iSelect Fund Management, Acre Venture Partners, Skyviews Life Science
- Series A, May 13, 2020, $4.5M — Seventure Partners, iSelect Fund Management

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A
- iSelect Fund Management (https://capitalatlas.ai/funds/iselect-fund-management) — Series A
- Collaborative Fund (https://capitalatlas.ai/funds/collaborative-fund) — Series A
- Acre Venture Partners (https://capitalatlas.ai/funds/acre-venture-partners) — Series A
- Skyviews Life Science (https://capitalatlas.ai/funds/skyviews-life-science) — Series A
- Morado Ventures (https://capitalatlas.ai/funds/morado-ventures) — Series A
- Alpha Edison (https://capitalatlas.ai/funds/alpha-edison) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A
- ReMy Ventures (https://capitalatlas.ai/funds/remy-ventures) — Series A
- E12 Ventures (https://capitalatlas.ai/funds/e12-ventures) — Series A
- DSM-firmenich — Series A